acute myocardial infarction | versus other fibrinolytic No demonstrated result for efficacy | 1 trial | meta-analysis | | Trial | control | p<0.05 | harm | NS |
---|
InTIME-II, 2000 | lanoteplase vs accelerated t-PA | | | Mortalité à long terme 0.97 [0.88; 1.07] Hémorragies majeures précoces 0.83 [0.53; 1.31] Mortalité précoce 1.02 [0.90; 1.16] AVC précoce 1.22 [0.94; 1.59] |
Trial | Treatments | Patients | Method |
---|
InTIME-II, 2000 | lanoteplase 120 KU. kg(-1) as a single intravenous bolus (n=10038) vs. up to 100 mg accelerated alteplase given over 90 min (n=5022) | patients presenting within 6 h of onset of ST elevation acute myocardial infarction | double blind Parallel groups Sample size: 10038/5022 Primary endpoint: Mortality 30-day FU duration: 30 days |
|